The counter-therapeutic effect of this commonly used chemotherapy provides a new approach to how doxorubicin, surprisingly, can influence the promotion of cancer spread, and how these activating changes can be decreased by blockade of VEGFR3 signaling. This evidence concerns the gene FLT4 and cancer.